Crescita Therapeutics Inc. has signed an exclusive distribution agreement with NanoPass Technologies Ltd. to launch and distribute the MicronJet 600 in Canada. Crescita is now pursuing Canadian regulatory approval of the product.

“MicronJet is a great addition to our medical aesthetic portfolio, enhancing our offerings alongside NCTF 135 HA, Art Filler, and Pliaglis. This novel device provides precision in penetration depth, no bruising and comfortable injection, all of which are welcomed by medical practitioners and patients alike,” Crescita President/CEO Serge Verreault stated. 
 
Leveraging MEMS technology, MicronJet is an intradermal injection device that offers a consistent and virtually pain-free delivery of aesthetic products and therapeutic substances. With three 0.6mm, silicon crystal-made delivery pyramids, MicronJet can be attached to standard syringes and will provide aesthetic clinicians with the least invasive and most precise intradermal delivery currently on the market, allowing administration to delicate and sensitive areas such as around the eyes, neck and décolleté area, as well as to the full face, for optimal patient outcomes. 
 
Crescita will launch MicronJet upon receiving Health Canada approval for the product (currently expected to be in the first half of 2025). MicronJet has been accepted by patients worldwide and is supported by more than 70 clinical studies and multiple peer reviewed publications. MicronJet is CE marked, cleared by the U.S. Food and Drug Administration, ISO 13485 certified, and approved in Australia as well as several other jurisdictions in Europe, Asia, and the Middle East.
 
“We’re thrilled to collaborate with Crescita to bring advanced delivery solutions to the Canadian market and support more clinicians in expanding their practice,” NanoPass CEO Daniel Levitats added. “This collaboration marks an exciting step in NanoPass’s commercial growth goals towards becoming the new intradermal delivery standard.”
 
Crescita Therapeutics is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The company offers a portfolio of science-based non-prescription skincare products and a commercial stage prescription product. The firm also owns multiple proprietary transdermal delivery platforms that support development of patented formulations to facilitate the delivery of active ingredients into or through the skin. 
 
NanoPass develops intradermal delivery technology, specializing in cutting-edge therapeutic and medical aesthetic delivery solution platforms.